CN109996536B - 抗真菌干燥粉末 - Google Patents

抗真菌干燥粉末 Download PDF

Info

Publication number
CN109996536B
CN109996536B CN201780063648.5A CN201780063648A CN109996536B CN 109996536 B CN109996536 B CN 109996536B CN 201780063648 A CN201780063648 A CN 201780063648A CN 109996536 B CN109996536 B CN 109996536B
Authority
CN
China
Prior art keywords
dry powder
respirable dry
itraconazole
formulation
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780063648.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109996536A (zh
Inventor
J·M·佩里
J·C·宋
D·L·哈瓦
R·C·桑德斯
H·S·特雷西
A·E·奥康纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmatrix Operating Co Inc
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of CN109996536A publication Critical patent/CN109996536A/zh
Application granted granted Critical
Publication of CN109996536B publication Critical patent/CN109996536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
CN201780063648.5A 2016-10-14 2017-10-13 抗真菌干燥粉末 Active CN109996536B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408376P 2016-10-14 2016-10-14
US62/408,376 2016-10-14
PCT/US2017/056497 WO2018071757A1 (en) 2016-10-14 2017-10-13 Antifungal dry powders

Publications (2)

Publication Number Publication Date
CN109996536A CN109996536A (zh) 2019-07-09
CN109996536B true CN109996536B (zh) 2023-03-07

Family

ID=60186406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780063648.5A Active CN109996536B (zh) 2016-10-14 2017-10-13 抗真菌干燥粉末

Country Status (12)

Country Link
US (3) US11116722B2 (https=)
EP (1) EP3525759A1 (https=)
JP (1) JP7085538B2 (https=)
KR (1) KR102408798B1 (https=)
CN (1) CN109996536B (https=)
AU (1) AU2017341815B2 (https=)
CA (1) CA3039485A1 (https=)
IL (1) IL265913B2 (https=)
MX (1) MX388733B (https=)
NZ (1) NZ752353A (https=)
RU (1) RU2766086C2 (https=)
WO (1) WO2018071757A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017144619A (ru) * 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP3781125A1 (en) * 2018-04-18 2021-02-24 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
AU2019256453B2 (en) * 2018-04-18 2024-10-17 Cipla Usa Inc. Methods of treating fungal infections
WO2021092349A1 (en) * 2019-11-08 2021-05-14 Scynexis, Inc. Lipid-based formulations of scy-078 salts
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030443A1 (it) 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
IT202000030437A1 (it) 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
WO2022187222A1 (en) * 2021-03-03 2022-09-09 Pulmatrix Operating Company, Inc. Dihydroergotamine dry power formulations and methods of use
WO2023086013A2 (en) * 2021-11-09 2023-05-19 Agency For Science, Technology And Research A salt-based antifungal powder platform formulation for aerosolization
EP4452235A1 (en) * 2021-12-20 2024-10-30 Pulmatrix Operating Company, Inc. Dry powder formulations of narrow spectrum kinase inhibitors
KR20250053839A (ko) 2022-06-21 2025-04-22 호비온 사이언티아 리미티드 당과 지질 복합입자를 포함하는 흡입용 결정형 약학 조성물 및 제조방법
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
CN120112290A (zh) 2022-08-31 2025-06-06 普马特里克斯营业公司 使用伊曲康唑干粉的方法
AU2024345688A1 (en) * 2023-09-20 2026-04-09 Cystetic Medicines, Inc. Use of a dry powder inhaler to treat or prevent pulmonary fungal infections

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054868A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
WO2014165303A1 (en) * 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US20150017244A1 (en) * 2011-12-09 2015-01-15 Galephar Pharmaceutical Research, Inc. Dry powder formulation of azole derivative for inhalation
CN104398497A (zh) * 2014-10-29 2015-03-11 中山大学 伊曲康唑吸入粉雾剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4097620A (en) 1977-05-02 1978-06-27 Xerox Corporation Magnetic toner particle coating process
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
MXPA05007156A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
US20050048127A1 (en) 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
MX2009001533A (es) 2006-08-11 2009-02-18 Panacea Biotec Ltd Particulas para el suministro de ingredientes activos, procedimiento de elaboracion y sus composiciones.
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
NO2252275T3 (https=) 2008-02-13 2018-04-28
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
MX2017009112A (es) * 2015-01-14 2018-06-15 Respira Therapeutics Inc Metodos y dispositivos de dispersion de polvo.
ES2936415T3 (es) 2017-04-17 2023-03-16 Respira Therapeutics Inc Inhalador de dosis unitaria de polvo seco

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054868A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US20020177562A1 (en) * 2000-12-21 2002-11-28 Michael Weickert Pulmonary delivery of polyene antifungal agents
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US20150017244A1 (en) * 2011-12-09 2015-01-15 Galephar Pharmaceutical Research, Inc. Dry powder formulation of azole derivative for inhalation
WO2014165303A1 (en) * 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN104398497A (zh) * 2014-10-29 2015-03-11 中山大学 伊曲康唑吸入粉雾剂及其制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles;Yajie Wang et al.;《International Journal of Pharmaceutics》;20111231;第424卷;第98-106页 *
Inhaled nano- and microparticles for drug delivery;Ibrahim M. El-Sherbiny et al.;《Global Cardiology Science and Practice》;20151231;第2卷;第1-14页 *
Levofloxacin Dry Powders Engineered for Efficient Pulmonary Delivery and Stability;Ciarán P. Lawlor et al.;《Respiratory Drug Delivery》;20141231;第549-552页 *
New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis;Christophe Duret et al.;《International Journal of Nanomedicine》;20121231;第7卷;第5475-5489页 *
Study of the preparation of amorphous Itraconazole formulations;María P. Fernández-Ronco et al.;《Crystal Growth & Design》;20150413;第15卷(第6期);第2686-2694页 *

Also Published As

Publication number Publication date
RU2019114112A3 (https=) 2021-02-12
KR102408798B1 (ko) 2022-06-13
MX2019004322A (es) 2019-12-11
AU2017341815B2 (en) 2023-06-15
AU2017341815A1 (en) 2019-05-02
IL265913B2 (en) 2024-07-01
US20240285523A1 (en) 2024-08-29
JP7085538B2 (ja) 2022-06-16
IL265913B1 (en) 2024-03-01
IL265913A (en) 2019-06-30
CN109996536A (zh) 2019-07-09
BR112019007459A2 (pt) 2019-07-16
EP3525759A1 (en) 2019-08-21
JP2019534270A (ja) 2019-11-28
RU2766086C2 (ru) 2022-02-07
NZ752353A (en) 2023-06-30
US20200129428A1 (en) 2020-04-30
US11116722B2 (en) 2021-09-14
MX388733B (es) 2025-03-20
KR20190068591A (ko) 2019-06-18
US20250221928A1 (en) 2025-07-10
RU2019114112A (ru) 2020-11-16
CA3039485A1 (en) 2018-04-19
WO2018071757A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
CN109996536B (zh) 抗真菌干燥粉末
JP7549534B2 (ja) イトラコナゾールを含む肺内投与のための抗真菌配合物
US20190167579A1 (en) Itraconazole dry powders
CN116687887A (zh) 用于吸入的干粉制剂
AU2019256453B2 (en) Methods of treating fungal infections
AU2022228443B2 (en) Dihydroergotamine dry powder formulations and methods of use
US20250049717A1 (en) Dry powder formulations of narrow spectrum kinase inhibitors
US20260048049A1 (en) Methods for treating cancer using inhaled angiogenesis inhibitor
RU2820457C2 (ru) Способы лечения грибковых инфекций
NZ793053A (en) Antifungal dry powders
BR112019007459B1 (pt) Pós secos antifúngicos e uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant